It made sense, therefore, to use periostin levels as a biomarker for anti–IL-13 therapy particularly because some patients with uncontrolled asthma continue to have increased levels of IL-13 in the sputum, despite the use of systemic corticosteroids and ICSs.54 This evidence concerns the gene IL13 and asthma.